Novavax Phase 3 CIC & flu vaccine candidates show robust immune responses, well tolerated

NOVAVAX INC

COVID-19-Influenza Combination (CIC) and stand-alone flu vaccine candidates induced 2.4-5.7-fold immune responses over baseline.
Both candidates well tolerated; >98% of solicited adverse events mild or moderate in severity.
Results from initial cohort of Phase 3 trial in adults 65+; similar to licensed comparators Nuvaxovid and Fluzone HD.
Novavax continues to pursue partnering opportunities to advance further development of these programs.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.